US2022119848A1PendingUtilityA1

Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription

Assignee: CHARPENTIER EMMANUELLEPriority: May 25, 2012Filed: Oct 29, 2021Published: Apr 21, 2022
Est. expiryMay 25, 2032(~5.8 yrs left)· nominal 20-yr term from priority
H10P 14/6512H10P 14/20H10H 20/0137C12N 9/22C12N 2310/3519A61P 35/00C12N 2310/13C12N 15/102A01K 67/027A61P 31/00C12Y 301/04C12N 15/111C12N 2800/80A61P 31/12C12N 2310/11C12N 2310/31C12N 2310/14C12N 2310/32A61K 48/00C12N 2310/531C12N 15/902C12N 15/90A61P 43/00A61K 38/465A61P 31/04A01H 6/4684C12N 15/907C12N 15/113C12N 2310/20C12N 15/63C12Q 1/686C12N 15/70Y02A50/30C12N 5/10C07K 2319/85C07K 2319/71C12N 2310/33C12N 15/746C12N 9/226
84
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A bacterial cell comprising a chimeric Cas9 protein comprising a Cas9 polypeptide fused to a transcription repressor, wherein the Cas9 polypeptide comprises one or more mutations in a RuvC domain and/or an HNH domain. 
     
     
         2 . A composition comprising:
 a buffer, and   a DNA encoding a single-molecule DNA-targeting RNA having the structure:   
       
         
           
           
               
               
           
         
         wherein the linker is nnnn such that the single-molecule DNA-targeting RNA has the nucleotide sequence nnnnnnnnnnnnnnnnnnnnGUUUUAGAGCUAnnnnUAGCAAGUUAAAAUAAGGCUAGUCCG (SEQ ID NO: 680). 
       
     
     
         3 . The composition of  claim 2 , wherein the linker is GAAA such that the single-molecule DNA-targeting RNA has the structure: 
       
         
           
           
               
               
           
         
         wherein “20-nt targeting seq” is nnnnnnnnnnnnnnnnnnnn. 
       
     
     
         4 . A method of cleaving a target DNA, the method comprising:
 contacting a target DNA with:   (a) the single molecule DNA-targeting RNA encoded by the DNA of the composition of claim  32 , wherein the nucleotide sequence of the single-molecule DNA-targeting RNA is GAUUUCUUCUUGCGCUUUUUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCG (SEQ ID NO: 321); and   (b) a Cas9 protein comprising the  S. pyogenes  Cas9 amino acid sequence set forth as SEQ ID NO.: 2,   wherein prior to said contacting the target DNA is double stranded and comprises a nucleotide sequence taatgaattccccaatacccaaaaagcgcaagaagaaatcaaccagcgca (SEQ ID NO: 302) hybridized to a nucleotide sequence tgcgctggttgatttcttcttgcgctttttgggtattggggaattcatta (SEQ ID NO: 301),   wherein said contacting does not take place inside of a cell, and   wherein the target DNA is cleaved.

Join the waitlist — get patent alerts

Track US2022119848A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.